Video Tumor Board Study for Skin Cancer Patients
Studies video expert meetings that plan treatment for melanoma patients, wherever they live.
Plain-language title generated from the registry record
Registry title: Video-Tumorboard PLUS
Key facts
- Where
- Bonn, Dresden, and Münster, GermanySee the 3 sites
Where in Germany
- Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum BonnBonn, GermanyNot yet recruiting
- Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitätsklinikum DresdenDresden, GermanyTaking people
- Westdeutsches Tumorzentrum Münster, Universitätsklinikum MünsterMünster, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Muenster
- Trial code
- NCT06980740
- Record updated
- 20 May 2025
- Original description
In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.Read full original descriptionShow less
Video-Tumorboard PLUS
In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.
Inclusion: The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board ; Minimum age 18 years; Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:; Malignant melanoma from stage IIB; Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB; In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved; has a medical license; has dermatological patients who are eligible to be presented in the vTB+.
Exclusion: Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy; Patients will be excluded from the study if they meet the following criteria:; No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.